ARIES for Vasculogenic Erectile Dysfunction (AriesIDE#1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02620982|
Recruitment Status : Completed
First Posted : December 3, 2015
Last Update Posted : September 29, 2016
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Erectile Dysfunction Sexual Dysfunction, Physiological||Device: ARIES (Extracorporal Shock Wave Application)||Phase 1|
An increasing number of men are suffering from the effects of Erectile Dysfunction (ED) each year. The development of oral therapies (phosphodiesterase 5 inhibitors) has been successful for many with the disease. However, these drugs may be contraindicated in patients with cardiovascular risk factors (which are often predecessors to developing ED) and are often ineffective in patients with other comorbid conditions, such as diabetes mellitus. The main objective of this study is to determine the safety and efficacy of low-intensity extracorporeal shock wave therapy using the Dornier Aries in the treatment of erectile dysfunction of vasculogenic origin.
This protocol allows for treatment of 23 men with 21-75 years of age with vasculogenic erectile dysfunction of at least 6 months' duration with low intensity extracorporeal shock wave therapy utilizing the Dornier Aries device.
This protocol includes the application of 5000 shockwaves per session in 5 treatment areas with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while moving the applicator along the penile shaft within the treatment areas. The maximum energy applied during this treatment would be 23.35J.
Conversely, the treatment protocol described within is designed to actually restore penile function as a disease-modifying therapy, and is not expected to require a maintenance regimen or continued treatments, as previous studies have demonstrated retained benefits at six months after the end of treatments.
Dornier MedTech hired an independent party to monitor data and perform internal audits to ensure the precision, quality, and integrity of the data collected. The investigator(s) agrees to permit access to study records, source data, and source documents for this purpose.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Low-Intensity Extracorporeal Shock Wave Therapy for the Treatment of Vasculogenic Erectile Dysfunction|
|Study Start Date :||December 2015|
|Actual Primary Completion Date :||September 2016|
|Actual Study Completion Date :||September 2016|
Experimental: ARIES Application
Low intensity Extracorporeal Shockwave Application utilizing the Dornier Aries
Device: ARIES (Extracorporal Shock Wave Application)
The treatment protocol includes 1 treatment per week for 6 weeks and an application of 5000 shockwaves per session in 5 treatment areas with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while moving the applicator along the penile shaft within the treatment areas. The maximum energy applied during this treatment would be 23.35J.
- Changes in the mean of the International Index of Erectile Function ED Domain ("IIEF-ED") scores, in the absence of severe adverse events. [ Time Frame: 1 month and 3 months ]Changes in the mean of the International Index of Erectile Function ED Domain ("IIEF-ED") scores, in the absence of severe adverse events. Higher scores indicate improved functionality according to the minimal clinically important difference (MCID) in erectile function from Rosen et al. 2011.
- Changes in penile base and tip rigidity [ Time Frame: 3 months ]Changes in penile base and tip rigidity as measured by penile plethysmography (Rigiscan) of the penis will be evaluated and reported.
- Changes in penile cavernosal artery peak systolic velocity (PSV) in [cm/s] by Penile doppler ultrasonography [ Time Frame: 3 months ]Changes in penile cavernosal artery peak systolic velocity in [cm/s] as determined by color measurement of Penile doppler ultrasonography
- Changes in penile corporal fibrosis [ Time Frame: 1 month, 3 months ]changes in penile corporal fibrosis as determined by gray scale assessment as measured by duplex ultrasound of the penis during pharmacologic erection will be evaluated and reported
- Changing in Erection Hardness score (EHS) [ Time Frame: 1 month, 3 months ]EHS increase in patients with EHS < 2.
- Changes in mean scores of the entire IIEF [ Time Frame: 1 month, 3 months ]Changes in mean scores of the entire IIEF will be evaluated and reported.
- Changes in mean scores of the SEP [ Time Frame: 1 month, 3 months ]Changes in mean scores of Sexual Encounter Profile (SEP); [Unit on a Scale], will be evaluated and reported.
- Changes in mean scores of the GAQ [ Time Frame: 1 month, 3 months ]Changes in mean scores of Global Assessment Questionnaire (GAQ); [Unit on a Scale], common, will be evaluated and reported.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||21 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
- Age 21 - 75 years
- Presence of Erectile Dysfunction for at least 6 months
- Having some response to a PDE5i or injection therapy (ICI) without penile scarring
- Vasculogenic ED
- IIEF-ED score ≥11 up to ≤25 while taking PDE5i or on ICI
- In a stable heterosexual relationship of more than three months' duration
- Agree to suspend all ED therapy for duration of study
- Agree to maintain their normal sexual habits
- Consent to participate
- Radical prostatectomy
- Previous radiation therapy to pelvis
- Previous stem cell or platelet rich plasma therapy
- Previous pelvic surgeries
- Untreated Hypogonadism or thyroid disease
- Hormone usage, other than testosterone, clomiphene or thyroid medication
- Illicit drug usage as demonstrated in the drug screen
- Psychogenic ED
- Peyronie's Disease or penile curvature that negatively influences sexual activity
- Current anticoagulation therapy or significant hematological conditions
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02620982
|United States, California|
|San Diego Sexual Medicine|
|San Diego, California, United States, 92120|
|Principal Investigator:||Irwin Goldstein, M. D.||San Diego Sexual Medicine|
|Responsible Party:||Dornier MedTech Systems|
|Other Study ID Numbers:||
|First Posted:||December 3, 2015 Key Record Dates|
|Last Update Posted:||September 29, 2016|
|Last Verified:||September 2016|
Sexual Dysfunction, Physiological
Sexual Dysfunctions, Psychological